Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD) : A review on etiological and pathogenetic aspects
Copyright © 2021 Elsevier Inc. All rights reserved.
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 234(2022) vom: 07. Jan., Seite 108916 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2022
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Review Crohn's disease Drugs Inflammatory bowel disease Ulcerative colitis Immune Checkpoint Inhibitors Immunologic Factors Interleukins Tumor Necrosis Factor-alpha plus... |
| Résumé: | Copyright © 2021 Elsevier Inc. All rights reserved. In recent years, therapeutic agents affecting the immune system have been largely implemented in the treatment of various hematological, rheumatological and dermatological disorders. Their clinical use has offered important benefits for affected patients and has also ameliorated clinical outcome and prognosis in many cases. Nonetheless, as any treatment, the use of these drugs may be associated with side effects. One of the target organs in such cases is the gastrointestinal tract. In particular, the exacerbation or the onset of inflammatory bowel disease (IBD) in treated patients is not infrequent, although the mechanism of action of these agents may be different. In this review we will focus on the use of therapeutic agents affecting the immune system and the development or exacerbation of IBD, with a mention on the possible underlying pathogenetic mechanisms |
|---|---|
| Description: | Date Completed 25.02.2022 Date Revised 25.02.2022 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2021.108916 |